Literature DB >> 17195138

Histopathology of pulmonary fibrotic disorders.

Chi K Lai1, W Dean Wallace, Michael C Fishbein.   

Abstract

Interstitial lung diseases encompass a broad spectrum of disorders that vary greatly in their clinical presentation, natural history, pathology, pathogenesis, prognosis, and treatment. Their correct classification requires integration of clinical, radiological, and pathological findings. Although these disorders may be well defined, interpretation of lung biopsy findings is often difficult, with surprisingly significant interobserver variability. This article reviews the histopathology of the major interstitial lung diseases, including the idiopathic interstitial pneumonias and pulmonary fibrotic disorders associated with collagen vascular diseases and smoking. In addition, the differential diagnosis of each of these disorders is discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17195138     DOI: 10.1055/s-2006-957333

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  3 in total

1.  Adiponectin attenuates lung fibroblasts activation and pulmonary fibrosis induced by paraquat.

Authors:  Rong Yao; Yu Cao; Ya-rong He; Wayne Bond Lau; Zhi Zeng; Zong-an Liang
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

2.  Requirement of bic/microRNA-155 for normal immune function.

Authors:  Antony Rodriguez; Elena Vigorito; Simon Clare; Madhuri V Warren; Philippe Couttet; Dalya R Soond; Stijn van Dongen; Russell J Grocock; Partha P Das; Eric A Miska; David Vetrie; Klaus Okkenhaug; Anton J Enright; Gordon Dougan; Martin Turner; Allan Bradley
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

3.  Location and dynamic changes of inflammation, fibrosis, and expression levels of related genes in SiO2-induced pulmonary fibrosis in rats in vivo.

Authors:  Zhao-Qiang Zhang; Bo Shao; Gui-Zhi Han; Gen-Yi Liu; Chun-Zhi Zhang; Li Lin
Journal:  J Toxicol Pathol       Date:  2019-08-10       Impact factor: 1.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.